Carol N. Rizkalla, MD

I am a huge proponent of educational webinars for learning 🧠 #PathWebinarPearls

👇👇👇is a compiled list of societies that regularly host educational webinars- many of which I have listened to myself! Most of these are FREE for residents, you may need to register as a member.

#USCAP2025 w/ Dr @marthabpitman

Sometimes cytopathology cannot go further than “atypical” —> molecular can help!

KRAS → neoplasm
GNAS → IPMN
no high-risk mutations + b9 imaging → observe
high risk muts (ex. SMAD4) → resect

#PathWebinarPearls

#USCAP2025 with Dr @MerceJorda1

Hyperchromasia is no longer a major criterion for high grade urothelial carcinoma @ParisSystem2- some high grades have glassy nuclei like polyomavirus, others have jet black chromatin instead of clumped —> still HGUC

#PathWebinarPearls

#USCAP2025 with Dr @MerceJorda1

Strict criteria for atypical urothelial cells is 🔑, or we get into issues where everything is called atypical and the diagnosis loses clinical value. @ParisSystem2 👇👇
“⬆️ NC due to nuclear enlargement”- major criteria

#PathWebinarPearls

#USCAP25 What constitutes an “urgent & or unexpected diagnosis” varies

@Pathologists has recommendations for this scenario (part of accreditation checklist!)- ultimately depends on relationship with clinicians, institutional policy, & pathologists discretion

#PathWebinarPearls